No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OII Oceaneering International
- 26.210
- +0.060+0.23%
Close Jul 23 16:00 ET
- 26.350
- +0.140+0.53%
Post 16:53 ET
2.66BMarket Cap24.73P/E (TTM)
26.440High25.990Low1.01MVolume26.060Open26.150Pre Close26.48MTurnover1.01%Turnover Ratio27.59P/E (Static)101.39MShares27.46052wk High4.27P/B2.61BFloat Cap18.66552wk Low--Dividend TTM99.61MShs Float79.892Historical High--Div YieldTTM1.72%Amplitude1.929Historical Low26.211Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Notable Earnings After Wednesday's Close
Oceaneering Q2 2024 Earnings Preview
Oceaneering International (NYSE:OII) Is Doing The Right Things To Multiply Its Share Price
Oceaneering (OII) to Report Q2 Earnings: What's in Store?
Should You Be Adding Oceaneering International (NYSE:OII) To Your Watchlist Today?
Oceaneering Is Maintained at Buy by Citigroup
Comments
The modest level of insider ownership and lack of insider transactions in the last three months suggest alignment with shareholder interests. However, significant insider selling over the past year could be a red flag for investors.
Insiders At Oceaneering International Sold US$2.5m In Stock, Alluding To Potential WeaknessOceaneering International, Inc.'s transition from loss to profitability justifies its strong share price gain. Despite slowing gains, the company's future financial health remains crucial for shareholders.
Oceaneering International's respectable ROE is overshadowed by its high debt level. Investors should consider the company's performance potential in less favorable credit markets. High ROE without debt typically indicates a high-quality business.
Gainers:
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
18
7
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg